Latest News
Positive Results: Pembrolizumab and Chemotherapy Combo Improves Pathological Complete Response in High-Risk ER+/HER2- Breast Cancer Patients
Oncologyme
/ Nov 03, 2023
Groundbreaking Breakthrough: Alectinib Revolutionizes Treatment for Completely Resected ALK-Positive NSCLC
Oncologyme
/ Oct 29, 2023
Enfortumab Vedotin and Pembrolizumab: Transforming First Line Treatment for Advanced Urothelial Cancer, a Landmark Breakthrough in Decades
Oncologyme
/ Oct 29, 2023
Dose-Dense MVAC Outperforms GC for MIBC: VESPER Trial Update Reveals Enhanced Overall and Disease-Specific Survival
Oncologyme
/ Oct 18, 2023
Comparison of Neoadjuvant Chemotherapy Plus Surgery and Concomitant Chemoradiotherapy in Stage IB2 to IIB Cervical Carcinoma: Insights from EORTC-55994 Trial
Oncologyme
/ Oct 17, 2023
Comparison of Neoadjuvant Chemotherapy Plus Surgery and Concomitant Chemoradiotherapy in Stage IB2 to IIB Cervical Carcinoma: Insights from EORTC-55994 Trial
Oncologyme
/ Oct 17, 2023
Promising Outcomes of Combined Therapy in Metastatic Castration-Sensitive Prostate Cancer: Findings from the PEACE-1 Trial
Oncologyme
/ Oct 17, 2023
Improving Clinical Outcomes in Refractory RAS Wild-Type MCRC: The Velo Trial Shows Promise with Panitumumab and Trifluridine-Tipiracil
Oncologyme
/ Oct 10, 2023
Latest Videos
IDEA analysis
Oncologyme
/ Apr 30, 2023
In the single center, randomized trial conducted in TATA Memorial...
Oncologyme
/ Apr 30, 2023
EGFR gene structure and signaling in NSCLC
Oncologyme
/ Mar 30, 2023
POSITIVE trial - short-term oncologic pregnancy safety results
Oncologyme
/ Mar 30, 2023
Neoadjuvant Therapy for TNBC
Feb 07, 2023
GIT Cancers 2022 Updates
Prof. Noha Foad
/ Feb 07, 2023
Hematologic Cancers 2022 Updates
Prof. Ahmed Magdy
/ Feb 07, 2023
Hot Issues in Breast Cancer and Pregnancy
Feb 07, 2023
Metastatic Breast Cancer 2022 Updates
Feb 07, 2023
Latest Articles
Latest Podcasts
Neoadjuvant Therapy for TNBC
In this episode, we enjoy a detailed discussion on neoadjuvant therapy for triple-negative breast cancer with two international experts: Prof. Mohsen Mokhtar and Prof. Ha...